DC Advisory (DC) advised Taisho Pharmaceutical Co Ltd (Taisho) on the acquisition of Bristol-Myers Squibb’s 97.97% stake in Bristol-Myers Squibb Indonesia Tbk (BMSI). Taisho also acquired the SEA operations of Bristol-Myers Squibb Co, namely the certain product registrations, trademarks and related assets of selected pharmaceutical and over-the-counter products sold primarily in Indonesia, Thailand, and the Philippines, as well as in other countries in the Asia Pacific region.
The antipyretic analgesic, (Tempra), and the anti-inflammatory analgesic for external use, (Counterpain), are brand assets. Tempra boasts a large share in the Indonesian and Philippines analgesic markets, and Counterpain holds a large share in the Indonesian and Thai anti-inflammatory analgesic for external use markets.
By merging knowledge, technology and sales know-how developed by Taisho, with the strong sales network built by BMSI in Asia, it will be possible to increase sales of both BMSI’s products and Taisho’s existing products.
With a manufacturing plant on a 25,440m2 site in the suburbs of Jakarta, BMSI is expected to act as producer for Taisho’s future business growth strategies within Asia.